FindTrial
Sign In

A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.

A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000036952
Enrollment
150
Registered
2019-06-04
Start date
2019-06-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who are suspected Parkinson&#39

Interventions

18F-FDOPA, 11C-Raclopride PET

Sponsors

Nagoya City Rehabilitation Agency
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who have intention to participate in the PET study and are suspected having Parkinson's disease or related disorders.

Exclusion criteria

Exclusion criteria: Patients having history of seizure, alcoholism, or any kind of drug dependency. Patients recognized to be inappropriate by anyone of attending physicians or study staffs.

Design outcomes

Primary

MeasureTime frame
Comparison of conditions of dopamine metabolism and D2 receptor function among disorders.—

Secondary

MeasureTime frame
Relationship between clinical pictures and conditions of dopamine metabolism or D2 receptor function.—

Countries

Japan

Contacts

Public ContactYoshihiko Horimoto

Nagoya City Rehabilitation Agency Department of Neurology

holly@nagoya-rehab.or.jp052-835-3811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026